The authors assessed the presence and frequency of the key cell types associated with effective anti-tumor immunity (namely CD8 and CD4 T lymphocytes) and found that neoadjuvant vaccination enables surgery to coincide with the peak of the vaccine induced immune response, resulting in increased frequency tumor-specific CD8 T cells present in the tumor, lymph nodes and resection area. This evidence concerns the gene CD4 and neoplasm.